Investors perceive that the departure of CBER head Vinay Prasad could end a period of regulatory unpredictability. The hope is for a return to more stable, agreed-upon development pathways, which is a critical factor for de-risking investments in biotech companies.
Beyond pitching to investors, biotech conferences like BioEquity Europe offer emerging companies a critical opportunity to connect with industry analysts and media. This builds relationships that lead to inclusion in market analysis and content, providing invaluable visibility and third-party validation.
The proposed pharma tariffs include a key loophole: the Secretary of Commerce can exempt any product by designating it a "specialty drug." This subjective clause opens the door for political influence, cronyism, and intense lobbying to secure exemptions, adding a layer of political risk for companies.
Middle East conflicts can spike oil prices and inflation, leading to higher interest rates. This disproportionately hurts smaller, cash-burning biotechs that rely on accessible capital, making them more vulnerable than larger firms during periods of global uncertainty.
The proposed pharma tariffs exempt companies with MFN (Most Favored Nation) deals, which are primarily large players. This gives them a strategic advantage in M&A, as they can acquire smaller, tariff-burdened companies and absorb their assets into a tariff-free structure, creating favorable deal dynamics.
Biogen's acquisition of Apellis, framed as adding growth drivers, is projected to deliver only mid-teen percentage growth for three years. This suggests a strategy of acquiring multiple moderate-growth assets rather than a single transformative blockbuster, highlighting the difficulty of finding home-run deals.
Eli Lilly’s $6.3B acquisition of a biotech with an orexin (OX2R) agonist is significant. The deal's contingent value rights (CVRs) are tied to indications outside of narcolepsy type 1, signaling big pharma's belief this mechanism has broad potential in larger sleep and neurological disorder markets.